Subcutaneous Biologics Market Worth to Outgrow by USD 279.38 billion By 2027
Posted On June 17, 2021
According to the research report by Value Market Research, the Global Subcutaneous Biologics Market is likely to grow to USD 279.38 billion by 2027 with a CAGR of 12.5% during the year 2021-2027. The rising prevalence of diseases like cancer, diabetes, psoriasis, etc has led to the increase in demand for subcutaneous biologics and is the key market driver for the growth of the subcutaneous biologics market. The increasing adoption of subcutaneous biologics in the healthcare sector is assumed to boost the market growth of subcutaneous biologics. Moreover, increasing the trend of self-administration among the consumers will further boost the market growth of subcutaneous biologics. However, allergic reactions caused due to biologics and strict regulatory requirements for approval of subcutaneous biologics may restrain the market's growth. But the high investment in the healthcare care sector and advancement in technology are expected to drive the market growth of subcutaneous biologics.
Biologics are pharmaceutical products developed using biological processes called biologics and include monoclonal antibodies, vaccines, and other protein-based therapeutic products. Biologics that can be delivered to patients through a subcutaneous route of administration are known as subcutaneous biologics and consist of sugar, nucleic acid, protein, or combinations of these substances. These have several advantages like patient convenience, self-administration, better therapy adherence, and reduced healthcare cost, etc. Therapeutic products that are currently delivered intravenously are also being reformulated for subcutaneous administration.
"Global Subcutaneous Biologics Market Report By Application By Subcutaneous Drug Delivery Systems (Prefilled Syringes, Wearable Injectors, Auto-Injectors, Drug Reconstitution Delivery Systems), By Applications (Crohn’s Disease, Rheumatoid Arthritis, Breast Cancer, Leukemia, Lymphoma, Psoriasis) And By Regions - Industry Trends, Size, Share, Growth, Estimation And Forecast, 2021-2027" is an elaborate report providing market data on the basis of segments and geography.
On the basis of subcutaneous drug delivery systems the market is segmented into Prefilled Syringes, Wearable Injectors, Auto-injectors, Drug Reconstitution Delivery Systems. By applications the subcutaneous biologics market is categorised as Crohn’s Disease, Rheumatoid Arthritis, Breast Cancer, Leukemia, Lymphoma, Psoriasis.By geography the report is bifurcated into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Subcutaneous Biologics is the dominating region. The data tables in this section depict the market estimate by market segment.
The Report Segments Global Subcutaneous Biologics Market -
By Subcutaneous Drug Delivery Systems
- Prefilled Syringes
- Wearable Injectors
- Drug Reconstitution Delivery Systems.
- Crohn’s Disease
- Rheumatoid Arthritis
- Breast Cancer
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Players Profiled In the Report:
Biogen Idec, Amgen, Inc., Genentech Inc., F. Hoffmann-La Roche AG, AbbVie, Inc., Eisai, Inc., Takeda Pharmaceutical Company Ltd., Pfizer Ltd., and Bristol-Myers Squibb.
Download the FREE SAMPLE of Global Subcutaneous Biologics Market Research Report
About Value Market Research -
Value Market Research was established with the vision to ease decision making and empower the strategists by providing them with holistic market information. Our analysts’ team is well equipped with all research tools and techniques and hold deep knowledge of the industry they are working for.
We ensure intellectual, precise and quality data is delivered to our client. We facilitate clients with syndicate research reports and customized research reports on 25+ industries with global as well as regional coverage.
Value Market Research
401/402, TFM, Nagras Road, Aundh, Pune-7.
Email: [email protected]